Table 1. dPCR KRAS mutation analysis in FFPE EUS-FNA pancreas biopsy specimens.

	Cytological Diagnosis
	Adenocarcinoma (N = 19)	Atypical cells (N = 10)	Negative for malignancy (N = 5)
Age (years, SD)	69 (10.8)	71 (10.4)	64 (15.6)
Surgically resected (N, %)	20 (100%)	10 (100%)	0
Surgical pathology diagnosis (N)	PDAC (19)	PDAC (1) MD-IPMN gastric subtype (5) BD-IPMN gastric subtype (3) PanIN (1)	N/A (no surgery)
FFPE EUS-FNA block cellularity (N, %) [number of cells/10-um section]
100–200	7 (31%)	2 (22%)	0
201–400	5 (23%)	2 (22%)	2 (40%)
401–600	5 (23%)	3 (33%)	1 (20%)
>600	5 (23%)	2 (22%)	2 (40%)
dPCR KRAS mutation analysis (N)
Mutated KRAS	19	9	0
WT KRASa	0	1b	5

^adPCR indicates absence of G12D or G12V mutation

^b WT KRAS found in the patient with BD-IPMN

Abbreviations: dPCR; digital PCR, WT; wild-type, PDAC; pancreas adenocarcinoma, MD-IPM; main duct intraductal papillary mucinous neoplasm, BD-IPMN; branch duct intraductal papillary mucinous neoplasm, PanIN; pancreas intraepithelial neoplasia